ORMP
Oramed Pharmaceuticals Inc
4.40$
-3.7%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +72.8% | +0.2% | +1.0% | +0.2% | -1.1% | -1.1% | +2.2% | +0.0% | +9.2% | -1.2% | +2.4% | -0.1% | -1.0% | +0.0% | +1.0% | +0.0% | -1.0% | -1.3% | +2.4% | +0.3% | -1.3% | -1.2% | +1.2% | +1.2% | -0.1% | -2.2% | +1.2% | -100.0% | – | – | – | – | – | – | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | +57.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -100.0% | – | – | – | +6,309.7% | -98.5% | +3.3% | -3.2% | +0.0% | -100.0% | – | |
| – | +19.8% | +44.4% | +1.0% | +0.2% | -1.1% | -1.1% | -12.1% | +16.2% | +3.6% | -4.4% | +11.6% | -0.1% | -1.0% | +0.0% | +1.0% | +0.0% | -1.0% | -1.3% | +2.4% | +0.3% | -1.3% | -1.2% | +1.2% | +1.2% | -0.1% | -2.2% | +1.2% | – | – | – | – | – | – | – | -330.8% | – | – | – | – | – | |
| – | -15.5% | +32.8% | -27.5% | +11.9% | -8.2% | +17.1% | +54.0% | -34.8% | +59.0% | -28.4% | +24.0% | -43.0% | -8.1% | +64.2% | -42.0% | +54.2% | +94.5% | -33.0% | +42.2% | +6.2% | +9.7% | -9.0% | +57.3% | -41.7% | +36.1% | -39.2% | -58.9% | -47.4% | +79.0% | -31.2% | +22.3% | +55.5% | -34.8% | +51.0% | -53.1% | +11.5% | +72.4% | -19.8% | -100.0% | – | |
| – | -24.4% | +81.8% | -40.7% | +85.1% | +8.7% | -2.5% | +5.2% | -1.0% | -9.8% | +14.3% | -15.6% | -8.1% | +30.9% | +28.7% | -26.0% | -29.1% | -0.4% | +128.9% | -22.1% | +73.4% | -22.7% | +215.8% | -53.9% | +20.9% | -10.9% | -53.7% | +94.1% | +6.0% | -18.8% | -15.5% | -5.0% | -50.0% | +151.9% | +8.1% | -36.9% | -12.4% | +189.2% | -43.9% | +33.9% | – | |
| – | -17.1% | +40.9% | -30.3% | +25.2% | -3.7% | +11.1% | +41.0% | -28.1% | +40.1% | -20.8% | +13.9% | -36.4% | +2.5% | +51.8% | -37.3% | +25.1% | +75.8% | -14.9% | +22.9% | +19.0% | +7.9% | +36.5% | +1.5% | -26.6% | +17.5% | -43.6% | -24.0% | -35.2% | +32.2% | -22.5% | +5.8% | -1.5% | +15.4% | +26.6% | -44.8% | -3.7% | +135.5% | -35.1% | -24.4% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -98.2% | -12.5% | -4.8% | – | – | +4.8% | +31.8% | – | – | +137.5% | -26.3% | – | – | -90.0% | +300.0% | +1,600.0% | -91.2% | +2,066.7% | +89.6% | +35.7% | -73.8% | +210.9% | -35.7% | +196.0% | +57.7% | -2.3% | -100.0% | – | +46.6% | -51.1% | -55.9% | +5,808.0% | +0.0% | -83.4% | -100.0% | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -88.5% | +606.5% | -270.8% | – | – | – | +352.6% | -83.5% | +404.6% | +105.5% | – | |
| – | -70.0% | -145.5% | – | – | – | – | – | – | – | – | -106.7% | – | – | -471.3% | – | -1,460.0% | – | – | – | – | – | – | – | – | -293.0% | – | – | – | – | – | – | -30.7% | -63.3% | +40.4% | -121.6% | – | -101.9% | – | +110.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -88.5% | +499.7% | -313.0% | – | – | – | +264.2% | -79.3% | +282.8% | +104.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +411.1% | -265.5% | – | – | – | +351.9% | -109.5% | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.